v1

Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts.

Terlipressin Acetate, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.

vMIP-II (1-21) (NT21MP) TFA (TFA is a potent inhibitor of CXCR4. This compound interacts broadly with CC and CXC chemokine receptors. Furthermore, vMIP-II (1-21) TFA inhibits CXCR4 by competing for binding sites with 125I-SDF-1R, exhibiting an IC50 value of 190 nM.

V1 iridoid is a useful organic compound for research related to life sciences and the catalog number is T124032.

Epsilon-V1-2, a Cys-conjugated, is a biologically active peptide known as the εPKC-specific inhibitor. It hampers εPKC functionality by obstructing its translocation and the phosphorylation of MARCKS, additionally perturbing εPKC's interaction with its anchoring protein, εRACK. The peptide includes a cysteine residue at its C-terminus, facilitating the formation of potential disulfide bonds with carrier proteins. Pyroglutamyl formation can occur spontaneously at the N-terminus if glutamine or glutamic acid is present, enhancing peptide stability against gastrointestinal proteases. Pyroglutamyl peptides, a recognized subset, are accounted for in the peptide's purity during HPLC analysis.

GV150013 is an antagonist of cholecystokinin-2 (CCK2) receptor.

MV151 is a cell-permeable, fluorescent, broad-spectrum proteasome inhibitor that specifically targets all active subunits of the proteasome and immunoproteasome in living cells and can be used to label the proteasome in vitro and in vivo.

VAV1 degrader-3 is an orally active and efficient VAV1 molecular glue degrader that reduces immune cell activation, proliferation, and cytokine production, useful for studying inflammation and autoimmune diseases.

VAV1 degrader-2 (Example 176) is a molecular gel degrader (DC50=4.41 nM) that targets VAV 1 for the study of inflammatory and autoimmune diseases.

TRV120056 acetate is a Gq-biased agonist with 10-fold greater molecular efficiency on AT1R-Gq fusion proteins than AT1R-βarr2 fusion proteins.

HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.

Nav1.1 activator 1 (compound 4) is an effective Nav1.1 agonist with blood-brain barrier permeability, exhibiting significant selectivity for Nav1.2, Nav1.5, and Nav1.6. It increases the decay time constant of Nav1.1 at 0.03 μM current and can be used for studying central nervous system disorders.

Nav1.7-IN-6, a selective inhibitor of Nav1.7.

NaV1.7 inhibitor-1, an efficacious inhibitor of voltage-gated sodium channel (NaV) 1.7 (IC50 of 0.6 nM for hNaV1.7).

Nav1.7-IN-2 is avoltage-gated sodium channels (Nav) inhibitor in particular Nav 1.7(IC50 of 80 nM).

Nav1.7-IN-3 is a selective and orally bioavailable inhibitor of voltage-gated sodium channel Nav1.7(IC50 of 8 nM).

Nav1.7 inhibitor is a Nav1.7 inhibitor for research in the field of pain and anesthesia.

Xanthone V1a is a useful organic compound for research related to life sciences and the catalog number is T126501.

MV1 is an antagonist of IAP. When combined with HaloTag ligand, MV1 causes protein knockdown of HaloTag-fused proteins.

T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 60 nM).

CV-1808 is a coronary vasodilator, antihypertensive, and antipsychotic following systemic administration in vivo. CV-1808 is an adenosine A2 receptor agonist.

PV1162 is a Chk2-specific inhibitor characterized by a potency with an IC 50 value of 0.29 nM. It operates by specifically targeting the gatekeeper-dependent hydrophobic pocket behind the ATP-binding site (adenine-binding region) to inhibit ATP binding to Chk2, effectively suppressing the phosphorylation activity of Chk2. This compound has demonstrated potential for application in cancer therapy.

TRPV1-IN-2 (( R ) -32) is an inhibitor of TRPV1. It provides protective effects in the ED epilepsy model.

TRPV1/CB2 agonist 1 (compound 41) is a dual agonist targeting hTRPV1 and CB2 receptors, with an EC50 value of 26.8 μM for hTRPV1. It is applicable in research related to the nervous system.